Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07VQW
|
||||
Former ID |
DNC001271
|
||||
Drug Name |
Sant7
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Multiple myeloma [ICD9: 203; ICD10:C90] | Investigative | [1] | ||
Company |
Sigma-Tau
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C20H27N7O13P2S
|
||||
Canonical SMILES |
C1=C(N=C(S1)C2C(C(C(O2)COP(=O)(CP(=O)(O)OCC3C(C(C(O3)N4<br />C=NC5=C4N=CN=C5N)O)O)O)O)O)C(=O)N
|
||||
InChI |
1S/C20H27N7O13P2S/c21-16-10-18(24-4-23-16)27(5-25-10)20-14(31)12(29)9(40-20)2-38-42(35,36)6-41(33,34)37-1-8-11(28)13(30)15(39-8)19-26-7(3-43-19)17(22)32/h3-5,8-9,11-15,20,28-31H,1-2,6H2,(H2,22,32)(H,33,34)(H,35,36)(H2,21,23,24)/t8-,9-,11-,12-,13-,14-,15-,20-/m1/s1
|
||||
InChIKey |
CRWWKLKZKYLFQV-HVIRUEHBSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Interleukin-6 receptor | Target Info | Antagonist | [1] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
HIF-1 signaling pathway | |||||
PI3K-Akt signaling pathway | |||||
Jak-STAT signaling pathway | |||||
Hematopoietic cell lineage | |||||
Non-alcoholic fatty liver disease (NAFLD) | |||||
Reactome | MAPK3 (ERK1) activation | ||||
MAPK1 (ERK2) activation | |||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Senescence and Autophagy in Cancer | |||||
IL-6 signaling pathway | |||||
Differentiation Pathway | |||||
Interleukin-6 signaling | |||||
References | |||||
REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.